• No results found

University of Groningen Circulating factors in heart failure Meijers, Wouter

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Circulating factors in heart failure Meijers, Wouter"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Circulating factors in heart failure

Meijers, Wouter

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Meijers, W. (2019). Circulating factors in heart failure: Biomarkers, markers of co-morbidities and disease factors. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen

Behorende bij het proefschrift:

Circulating Factors in Heart Failure

Door: Wouter C. Meijers

1. Biomarkers can help clinicians to identify heart failure patients with high risk for near-term hospitalization due to heart failure. This thesis

2. Assessing low risk does not equal the absence of high risk and biomarkers may help to properly utilize scarce resources. This thesis

3. Low levels of natriuretic peptides do not necessarily reflect low risk. This thesis

4. Indices of biological variation are mostly unknown to people who interpret

biomarker results but they are essential for proper interpretation. This thesis 5. Heart failure is an endocrine disease: circulating factors from the heart and

other organs contribute to the disease. This thesis

6. The failing heart stimulates tumor growth via circulating factors. This thesis

7. Be curious. Stephen Hawking

8. The most precious thing that we all have with us is time. Steve Jobs

9. We choose to go to the moon in this decade, not because it is easy, but because it is hard. John F. Kennedy

10. There is only one way to avoid criticism: do nothing, say nothing, and be nothing. Aristotle

Referenties

GERELATEERDE DOCUMENTEN

For this purpose, natriuretic peptides (NPs), a known cardiac and HF specific biomarker, and also galectin-3, a more general and fibrotic marker, but profoundly linked to

Supplemental Figure S1. Odds ratio for HF rehospitalization or death at different time points Forest plot for heart failure rehospitalization or all cause mortality within 30, 60,

As this analysis aimed to describe the value of biomarkers, and as NT-proBNP is a biomarker, we present the results for the various biomarkers on top of the clinical risk model

The exciting implication raised by the report is that a pre-discharge plasma galectin-3 concentration of <11.8 ng/mL may be incorporated into an algorithm identifying

We examined patients who had been enrolled in the Coordinating study evaluating Outcomes of Advising and Counselling in Heart Failure (COACH), with preserved

baseline and at 6 weeks; C Scatterplot of urinary galectin-3 levels at baseline and at 6 weeks; D Galectin-3 excretion rate in controls and chronic heart failure patients at

General population: PREVEND 50 – Prevention of REnal and Vascular ENd-stage Disease; Framingham 49 ; HF-ACTION 60 - Heart Failure: A Controlled Trial In- vestigating Outcomes

Therefore, our aim was to assess the conjoint analytical and biological variation of clinical established biomarkers N-terminal-pro-B-type natriuretic peptide NT-proBNP and